 | Up a level |
Ghielmini, M.; Rufibach, K.; Salles, G.; Leoncini-Franscini, L.; Léger-Falandry, C.; Cogliatti, S.; Fey, M.; Martinelli, G.; Stahel, R.; Lohri, A.; Ketterer, N.; Wernli, M.; Cerny, T.; Hsu Schmitz, S.-F. (2005). Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology, 16(10), pp. 1675-1682. Oxford University Press 10.1093/annonc/mdi320
Von Rohr, A.; Schmitz, S.-F. H.; Tichelli, A.; Hess, U.; Piguet, D.; Wernli, M.; Frickhofen, N.; Konwalinka, G.; Zulian, G.; Ghielmini, M.; Rufener, B.; Racine, C.; Fey, M. F.; Cerny, T.; Betticher, D.; Tobler, A. (2002). Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of oncology, 13(10), pp. 1641-1649. Oxford University Press 10.1093/annonc/mdf272
Betticher, D. C.; Ratschiller, D.; Hsu Schmitz, S.-F.; Von Rohr, A.; Hess, U.; Zulian, G.; Wernli, M.; Tichelli, A.; Tobler, A.; Fey, M. F.; Cerny, T. (1998). Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Annals of oncology, 9(7), pp. 721-726. Oxford University Press 10.1023/A:1008273131598
